Market Research Report
Global Antibacterial Drugs Market - 2019-2026
|Published by||DataM Intelligence||Product code||931259|
Delivery time: 1-2 business days
|Global Antibacterial Drugs Market - 2019-2026|
|Published: January 1, 2020||Content info:||
Global Antibacterial Drugs Market Overview
Antibacterial drugs are the components originated from natural and synthetic components to treat the bacterial infections. The market is accelerated by the increasing demand for new drugs and antibacterial resistance. The global antibacterial drugs market also has a significant pipeline of drugs which is one of the major driver. Many of the novel products in the development pipeline by the pharmaceutical companies are targeting new treatment pathways, route of administration, and mechanisms of action.
The global antibacterial drugs market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
Global Antibacterial Drugs Market Dynamics
Global Antibacterial drugs market growth is driven by increased demand for antibacterial drugs due to rising prevalence of bacterial infections globally, development of novel therapies, increase in government policies and increased funds from other public bodies.
Rising prevalence of bacterial infections is one of the dominating factor boosting the market. According to global burden of disease study 2015, lower respiratory tract infections (LRIs) have caused 2*74 million deaths. Diarrhoea was estimated to be a leading cause of death among all ages and caused 1*31 million deaths. According to TBFACTS.org it is estimated that 1.5 million people died from the disease in 2014, including 400,000 individuals who were also HIV positive. According to WHO in 2016, lower respiratory infections caused 3.0 million deaths, diarrheal diseases caused 1.4 million deaths and tuberculosis led to 1.3 million deaths.
Government initiatives are expected to boost the market over the period of forecast. For instance, in October 2015, WHO has launched the Global Antimicrobial Surveillance System (GLASS) which works with WHO Collaborating Centers and existing antimicrobial resistance surveillance network. TB drug resistance surveillance has been implemented in 188 countries over the past 24 years. Also, a joint initiative of WHO and Drugs for Neglected Diseases initiative (DNDi), encourages research and development through public-private partnerships for the antibiotic resistance. It is estimated that by 2023, the partnership aims to develop and produce up to four new treatments, through the improvement of existing antibiotics and fuelling of the entry of new antibiotic drugs.
The increased antibacterial resistance is leading to the development of newer antimicrobials with new modes of action which can act against the multi-drug resistant strains. According to WHO, in the US, 23,000 people die as a result of antibacterial resistance every year. To tackle this, On June 26, 2018, Achaogen's ZEMDRI™ (plazomicin) was approved by FDA for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis, caused by Enterobacteriaceae in patients who have limited treatment options.
Robust pipeline is expected to boost the global antibacterial drugs market over the period of forecast. In June 2018, around 42 new antibiotics are with the potential to treat the bacterial infections and are in clinical development. For instance, drugs in phase 1 include TP-271 and TP-6076 of Tetraphase Pharmaceuticals Inc which belong to tetracycline drug class. Drugs in phase 2 include Otsuka Pharmaceutical Co. Ltd's OPS-2071 of quinolone class.
However, genetic mutations, toxicity of antibacterial drugs are expected to hamper the market. For instance, spontaneous mutations acquired from other bacteria through horizontal gene transfer make the bacteria resistant to antibiotic. Also, toxicities related to antibacterial drugs like photosensitivity caused by fluoroquinolones are restraining the market.
Global Antibacterial Drugs Market Segment Analysis
On the basis of drug type, the global antibacterial drugs market is segmented into beta-lactams, aminoglycosides, tetracyclines, macrolides, sulfonamide, quinolones, and others.
Beta lactum antibiotics segment is expected to dominate the market over the period of forecast. This is owing to the recent FDA approvals, promising pipeline of the pharmaceutical companies. For instance, vabomere of Melinta Therapeutics Inc was approved on August 30 2017 for complicated urinary tract infection. Cefepime +AAI1019 of Allecra, Cefiderocol (S-649266) of Shionogi & Co. Ltd. and Sulopenem of Iterum Therapeutics are in phase 3 for the treatment of complicated urinary tract infections.
Tetracycline antibiotics segment is expected to grow at a high rate over the period of forecast. This is owing to the increased number of FDA approvals and the promising pipeline of key players. For instance, omadacycline of Paratek Pharmaceuticals Inc. was approved in October 2018 for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections. Xerava (eravacycline) of Tetraphase Pharmaceuticals was approved in August 2018 for treating complicated intra-abdominal infections. On March 15, 2018, Australian company Mayne Pharma has announced a launch of a generic version of doxycycline monohydrate immediate release capsules in the US. Several drugs in phase 1 are anticipated to be approved in the forecast period. For instance, KBP-7072 of KBP Bio Sciences Pharmaceutical Technical Co. Ltd and TP-271 of Tetra phase Pharmaceuticals Inc. are used for treating Community-acquired bacterial pneumonia.
On the basis of end-users, the global antibacterial drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail stores and drug stores segment is expected to grow at a significant over the forecast period. This is owing to the increase in number of retail drugs stores, and the availability of antibacterial drugs in the retail pharmacies and drugs stores. According to the survey conducted in 2014, the majority of drug stores around 93.5% were prescribing antibiotics, especially amoxicillin and trimethoprim-sulfamethoxazole (septrin). A multi-country survey conducted by the WHO showed that around 93% of people obtained their antibiotics from a pharmacy or medical store.
Global Antibacterial Drugs Market Geographical Analysis
North America is dominating the global Antibacterial Drugs market in 2018 and estimated to hold largest market size over the forecast period (2019-2026) owing to rising prevalence of infectious diseases, increased antibiotic resistance, government initiatives and increased FDA approvals in the region, high treatment rate and improved diagnosis.
Rising prevalence is one of the dominating factor propelling the market. FDA approved drugs in the region, high treatment rate and improved diagnosis. For instance, According to CDC in 2016, in US, there were around 9272 cases of tuberculosis, and 53,850 cases of salmonella.
Increased antibiotic resistance is expected to boost the market over the period of forecast. For instance, in 2013, CDC has reported that such infections will kill at least 23,000 people each year in the US alone. According to National Institute of Health, around 20,000 people in the US are infected with vancomycin-resistant enterococci every year, and less than 10% of those infections are fatal. According to WHO, in US, at least 2 million people have a treatment-resistant bacterial infection, and more than 23,000 people die as a result of this.
Government initiatives, like Generating Antibiotics Incentives Now (GAIN) Act in U.S., are expected to boost the market over the forecast period. In September 2014, US National Strategy for Combating Antibiotic-Resistant Bacteria was developed.
Increased number of FDA approvals in the region is expected to boost the market. For instance, Ceftazidime/avibactam (Avycaz) of Sanofi in February 1, 2018, Ceftolozane/tazobactam (Zerbaxa) of Astellas in June 3, 2018, Dalbavancin (Xydalba) of Lepetit Research Center/Vicuron and Oritavancin (Orbactiv) of Eli Lilly in 2014 are some of the drugs approved in US.
Antibacterial Drugs Market Competitive Landscape
Some of the major players in the Antibacterial drugs market are: Pfizer, GlaxoSmithKline (GSK) and Merck & Co., Novartis AG, Sanofi, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Allergan, Cempra and Insmed.
The key players are adopting various key strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Antibacterial Drugs market globally. For instance,
On July 17, 2019 FDA has approved Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) for the treatment of complicated urinary tract and complicated intra-abdominal bacterial infections.
On June 3, 2019, FDA has approved Merck's ZERBAXA® (ceftolozane and tazobactam) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
On February 1, 2018, Allergan plc has announced that the US FDA has approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ® (ceftazidime and avibactam) to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the susceptible Gram-negative microorganisms like Klebsiella pneumoniae, Enterobacter cloacae.
In March 2016, Obiltoxaximab of Elusys Therapeutics got FDA approval for Inhalational anthrax.
Global Antibacterial Drugs Market Methodology and Scope